Myriad Genetics (FRA:MYD) GF Value Rank: 2 (As of Jul. 31, 2026) — 67% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:MYD Myriad Genetics Inc FRA:MYD
58 GF Score
Price €4.33
GF Value €12.24
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Myriad Genetics GF Value Rank?

Myriad Genetics FRA:MYD -5.65% 58 GF Value Rank is 2 as of Jul. 31, 2026, which is 67% below its 10-year median of 6.00. GuruFocus rates FRA:MYD with a GF Score™ of 58/100 and a GF Value™ of €12.24 (Possible Value Trap). The stock has 5 warning signs investors should review.

Myriad Genetics has the GF Value Rank of 2.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Myriad Genetics GF Value Rank Related Terms


FRA:MYD vs FLGT, CSTL, BDSX: GF Value Rank Comparison

For the Diagnostics & Research subindustry, Myriad Genetics's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myriad Genetics GF Value Rank vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Myriad Genetics's GF Value Rank falls into.


FRA:MYD
58GF Score
Myriad Genetics Inc FRA:MYD
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 2 mean?
Myriad Genetics (FRA:MYD) has a GF Value Rank of 2 as of Jul. 31, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Myriad Genetics and its competitors. This is 67% below median its historical median of 6.00. Over the past decade, Myriad Genetics' GF Value Rank has ranged from 1.00 to 10.00.
Is Myriad Genetics' GF Value Rank too high?
Myriad Genetics' current GF Value Rank of 2 is 67% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Myriad Genetics has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' GF Value Rank compare to FLGT and CSTL?
Myriad Genetics' GF Value Rank of 2 can be compared against companies in the Medical Diagnostics & Research industry. Historically, Myriad Genetics' own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Medical Diagnostics & Research company?
A good GF Value Rank depends on the Medical Diagnostics & Research industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Myriad Genetics and its competitors. Myriad Genetics's current GF Value Rank is 2, which is 67% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (FRA:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €12.24, compared to a current price of €4.33 — trading 64.7% below its estimated fair value. The current GF Value Rank is 2, which is 67% below median its 10-year median of 6.00. Myriad Genetics' overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Myriad Genetics (FRA:MYD), the current GF Value Rank is 2 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Myriad Genetics (FRA:MYD) Overvalued in 2026?

Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued. The current stock price of €4.33 is trading 64.7% below its estimated GF Value™ of €12.24. GuruFocus considers Myriad Genetics to be Possible Value Trap.

Key valuation signals for FRA:MYD:

  • GF Value Rank: 2 (67% below median its 10-year median of 6.00)
  • GF Value™: €12.24 vs. price of €4.33 (64.7% below fair value)
  • GF Score™: 58/100 with 5 warning signs

No single metric tells the full story. See the FRA:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Myriad Genetics Business Description

Other Exchanges MYGN:USA0K3W:UK
Address 322 North 2200 West, Salt Lake City, UT, USA, 84116
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
58GF Score

Get the complete analysis for FRA:MYD

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.33
Price
€12.24
GF Value